87 related articles for article (PubMed ID: 30501733)
1. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Fan WJ; Wu T; Chen JW; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Castillo-Tokumori F; Talati C; Al Ali N; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e956-e960. PubMed ID: 32778513
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
[TBL] [Abstract][Full Text] [Related]
7. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Qu S; Xu Z; Qin T; Li B; Pan L; Chen J; Yan X; Wu J; Zhang Y; Zhang P; Gale RP; Xiao Z
Hematol Oncol; 2022 Oct; 40(4):787-795. PubMed ID: 35609279
[TBL] [Abstract][Full Text] [Related]
10. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
11. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Livun A; Newberry KJ; Manshouri T; Kusec R; Verstovsek S
Anticancer Res; 2015 Oct; 35(10):5219-23. PubMed ID: 26408680
[TBL] [Abstract][Full Text] [Related]
12. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
[No Abstract] [Full Text] [Related]
13. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Khan MA; Shahbaz N
J Coll Physicians Surg Pak; 2018 Jun; 28(6):S89-S90. PubMed ID: 29866231
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pathogenesis and drug treatment of myelofibrosis.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
[TBL] [Abstract][Full Text] [Related]
18. New and old treatment modalities in primary myelofibrosis.
Cervantes F; Mesa R; Barosi G
Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
El Rassi FA; Tam CS; Carwile J; Verstovsek S
Leuk Res; 2008 May; 32(5):821-2. PubMed ID: 17870158
[TBL] [Abstract][Full Text] [Related]
20. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]